ACADIA PHARMACEUTICALS INC Reports H1 2026 Financial Results

What Happened
Acadia Pharmaceuticals Inc. announced its financial results for the six months ended June 30, 2026 via a press release dated August 4, 2026, and furnished that press release as Exhibit 99.1 to an 8-K (Item 2.02). The company filed the 8-K on August 4, 2026; the report was signed by Jennifer J. Rhodes, Executive Vice President and Chief Legal Officer.

Key Details

• Filing date: August 4, 2026 (8-K reporting Item 2.02: Results of Operations and Financial Condition).
• Reporting period covered: six months ended June 30, 2026.
• Exhibit included: Press Release dated August 4, 2026 (Exhibit 99.1).
• Administrative note: Cover page interactive XBRL file included (Exhibit 104); report signed by Jennifer J. Rhodes.

Why It Matters
This 8-K furnishes Acadia’s latest earnings and revenue-related update for H1 2026; investors should review the attached press release for the company’s specific financial results, trends, and any commentary on business performance or guidance. Because the filing furnishes (rather than files) the press release, readers should open Exhibit 99.1 to see the full figures and management commentary that may affect valuation, analyst estimates, or near-term trading decisions.